• FDA cleared Immunome’s IND for IM-1340, a first-in-class antibody-drug conjugate for advanced solid tumors.
• Phase 1 trial is slated to start in Q4 2026 to assess safety, pharmacokinetics, and early anti-tumor activity.
• IM-1340 uses Immunome’s proprietary HC74 topoisomerase I inhibitor payload.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930301168) on September 30, 2026, and is solely responsible for the information contained therein.